denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
Myelodysplastic syndromes (MDS) constitute a heterogeneous set of disorders for which the management remains complex and is challenged by a variety of clinical presentations with mostly broad based approaches for treatment. Advances in understanding the pathobiology of myelodysplasias are driven by improved invent of mouse models that recapitulate the MDS phenotype rather than using leukemia-derived models. Furthermore, identification of somatic mutations in MDS have generated enthusiasm for the hope of targeted therapies, even if for only small subsets of patients. This educational session will explore the evidence for best practices for risk stratification for patients diagnosed with MDS. Treatment options for both lower risk and higher risk MDS patients will be discussed in detail and will include existing therapies, novel agents as well as hematopoietic stem cell transplant approaches.
Dr. Uwe Platzbecker will review the specifics of risk stratification for patients diagnosed with MDS. MDS are associated with varying degrees of cytopenias and clinical presentations. This poses a particular challenge to providers when counseling patients regarding prognosis and subsequent treatment. This educational session will review the established scoring systems and their advantages/disadvantages. Important considerations on use of the scoring systems include assessment of intermediate risk MDS as well as CMML. Current strategies to improve future precision of risk stratification will also be described.
Dr. Hetty Carraway will discuss the treatment options for patients diagnosed with lower risk MDS. She will review the approaches for patients with isolated cytopenias as well as the management of those MDS patients with multiple cytopenias. Therapeutic considerations regarding presence of somatic mutations will also be reviewed with regard to best treatment option (either now or in development).
Dr. Bart Scott will address the established and newer treatment options for higher risk patients diagnosed with MDS. While hypomethylating therapy has been the mainstay of therapy for this population, he will address the upcoming novel combination therapies that challenge this status quo. Dr. Scott will also provide an update on the use of hematopoietic stem cell transplant and the current approaches for patients eligible for this curative approach.
Dr. Uwe Platzbecker will review the specifics of risk stratification for patients diagnosed with MDS. MDS are associated with varying degrees of cytopenias and clinical presentations. This poses a particular challenge to providers when counseling patients regarding prognosis and subsequent treatment. This educational session will review the established scoring systems and their advantages/disadvantages. Important considerations on use of the scoring systems include assessment of intermediate risk MDS as well as CMML. Current strategies to improve future precision of risk stratification will also be described.
Dr. Hetty Carraway will discuss the treatment options for patients diagnosed with lower risk MDS. She will review the approaches for patients with isolated cytopenias as well as the management of those MDS patients with multiple cytopenias. Therapeutic considerations regarding presence of somatic mutations will also be reviewed with regard to best treatment option (either now or in development).
Dr. Bart Scott will address the established and newer treatment options for higher risk patients diagnosed with MDS. While hypomethylating therapy has been the mainstay of therapy for this population, he will address the upcoming novel combination therapies that challenge this status quo. Dr. Scott will also provide an update on the use of hematopoietic stem cell transplant and the current approaches for patients eligible for this curative approach.